1 mL BAC
13 units
resulting U-100 draw
- Concentration
- 5 mg/mL
- BAC added
- 1 mL
SinglePreclinicalPreclinicalVery Low confidenceSourced
TB-500
A synthetic fragment marketed by association with thymosin beta-4. Full-length thymosin beta-4 findings do not establish an injectable TB-500 protocol.
Evidence context, not a personal protocol
Quantities below reproduce their stated source context—label, human study, laboratory work or educational guide. They do not assess suitability, product equivalence or individual risk.
Community-reported schedule
Community-reported · not a validated scheduleCommunity dose schedule
Two community-provenance subcutaneous lines - a loading-then-maintenance pattern from a protocol author and an educational fragment titration. Community reports only, not a validated or trial-verified schedule.
Reported maximum quantityChoose the maximum quantity reported by this community line. Any earlier phase can be selected below for its arithmetic.
Reported quantities by phase
Select a point for its calculation examples- Acute (3x/day)650 mcgPer-injection acute anecdotes span roughly 350-650 mcg up to three times daily, dose-matched to BPC-157.
- Maintenance (2x/day)350 mcgStep down for maintenance
Vial-aware arithmetic
Reconstitution examples, up to 3 mL
Choose the vial quantity and BAC water first. The diagram and results below update for the selected 650 mcg reported quantity. Higher-strength vials may naturally land outside the 20-30 unit band.
BAC water selected
2 mL
Basic example limit: 3 mL maximum. Check the actual vial and product-specific limits.
U-100 draw26 U
20-30 U reference band
2 mL BAC
26 units
resulting U-100 draw
- Concentration
- 2.5 mg/mL
- BAC added
- 2 mL
Shown in the diagram. Closest of these examples to 25 units.
3 mL BAC
39 units
resulting U-100 draw
- Concentration
- 1.667 mg/mL
- BAC added
- 3 mL
Formula: draw units = selected mg × BAC mL ÷ vial mg × 100. The 20-30 unit band is a measurement reference, not a recommendation. Results are mathematical examples, not preparation instructions.
Dosage and protocol evidence
Each card states what the quantities are based on. A third-party or animal schedule is not a validated human dose.
Community GuideSubcutaneous in guideDaily
Third-party educational TB-500 schedule
500 mcg daily in weeks 1-2, 600 mcg in weeks 3-4, 750 mcg in weeks 5-8 and 1 mg in weeks 9-12
No controlled human TB-500 fragment study validates this schedule. Full-length thymosin beta-4 evidence must not be used as confirmation.
View sourceCommunity GuideSubcutaneous in reportsDaily for the fragment schedules
online research community fragment 17-23 discussion
Two supplier-derived fragment schedules are 750 mcg daily for 20 days or 450 mcg daily for 30 days
The same channel also repeats a 5 mg twice-weekly schedule likely inherited from full-length thymosin beta-4. The archive repeatedly warns that TB-500, full TB4 and fragments are conflated; raw/peptide-education/pe-tb-500-frag.md:18-32 and 378.
View sourceCommunity GuideSubcutaneous in reportsUp to 3x daily acute, reduced for maintenance
authenticated research-forum (Peppys) reports and a protocol author
Subcutaneous acute-injury anecdotes cluster around 350-650 mcg three times daily, stepping down to about 350 mcg twice daily for maintenance; reference charts list 450-750 mcg subcutaneously daily for 20-30 days, and an old long-acting form is dosed 1-2 mg two to three times weekly
Forum provenance from an authenticated archive with usernames omitted. The archive claims that what is sold today as TB-500 is actually short-acting TB4, which it uses to justify frequent daily dosing; that identity claim is recorded as a community assertion, not a validated equivalence, and the TB-500 fragment is kept separate from full-length thymosin beta-4.
View sourceEvidence summary
A synthetic fragment marketed by association with thymosin beta-4. Full-length thymosin beta-4 findings do not establish an injectable TB-500 protocol.
Protocol basis
The central evidence decision is molecule identity: a protocol cannot be imported from a different, full-length protein with different formulation and exposure.
Community provenance (Peppys)
An authenticated research-forum archive dose-matches TB-500 to BPC-157: subcutaneous acute-injury anecdotes cluster around 350-650 mcg up to three times daily, stepping down to about 350 mcg twice daily for maintenance, usually stacked with BPC-157. The archive asserts that material sold today as TB-500 is actually short-acting TB4 and uses that claim to justify frequent daily dosing; that equivalence is recorded as a community claim rather than validated fact, and the TB-500 fragment is kept separate from full-length thymosin beta-4. Usernames and post numbers are omitted. The planner above reproduces the arithmetic of these reported quantities; it does not validate them.
What remains uncertain
Human pharmacokinetics, dose-response, manufacturing standards and controlled outcomes are not established.
Warnings and contraindications
TB-500 fragment identity must not be conflated with full-length thymosin beta-4.
No adequate controlled human injection regimen for TB-500 was identified.
Animal wound-healing experiments do not establish human safety or effectiveness.
Shared across protocols
Supplies and general handling
Keep the universal checklist short. Product-specific labelling and source documentation always take priority over a general guide.
Research vial
Select the labelled vial quantity used in the calculation.
View Peppys vialBacteriostatic water
Use only a diluent appropriate to the research method and formulation.
View Peppys BAC waterU-100 measuring syringe
Use a new sterile device for every entry. Source locally.
Source locallyWipes and sharps container
Plan clean handling and immediate sharps disposal. Source locally.
Source locallyStorage follows the label
Do not apply a universal refrigerator rule. Follow the product, diluent and study documentation for temperature, light and expiry.
Use sterile equipment once
CDC injection-safety guidance calls for a new sterile needle and syringe for each injection and entry into a medication container.
Stability is formulation-specific
Do not infer a post-mixing lifetime from BAC water alone. Discard material when identity, integrity or sterility is in doubt.